The company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries, AstraZeneca states.

As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

Related article

AstraZeneca plans to increase investment and scope of Virginia facility

AstraZeneca will invest USD 4.5 billion in its new manufacturing facility in Virginia, a proposed increase of USD 500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments.

AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the company’s recently announced USD 50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver USD 80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

AstraZeneca’s commitment to the US and American patients is further reflected in the company’s largest single investment in a manufacturing facility to date, where the company broke ground in Virginia.

AstraZeneca’s commitment to the US and American patients is further reflected in the company’s largest single investment in a manufacturing facility to date, where the company broke ground in Virginia, it states. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.

The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately USD 20 billion of overall value to the American economy.